


PCT  
#5



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	RABUSSAY, Dietmar P.	Examiner:	To Be Assigned
Patent No.:	1C/516,757	Group Art Unit:	To Be Assigned
Filed:	December 4, 2004	Docket:	GTI-1490-US
Title:	Minimizing metal toxicity during electroporation enhanced delivery of polynucleotides		

INFORMATION DISCLOSURE STATEMENT (1)

RECEIVED  
5 FEB 2007  
Legal Staff  
International Division

Mail Stop: AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir/Madam,

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Information Disclosure Statement be entered and the documents listed on the attached Form SB08A be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the SB08A form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

The listed documents are being submitted in compliance with 37 CFR § 1.97(b), before the mailing date of the first office action on the merits.

CERTIFICATE OF MAILING PURSUANT TO 37 CFR § 1.8:

The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop: AMENDMENT, Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450

\_\_\_\_\_  
Daniel M. Chambers  
(Printed Name)  
  
\_\_\_\_\_  
Signature

22 Dec 2006  
(Date of Deposit)


If any fees are due, please contact the undersigned attorney at (858) 350-9690.

The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

Date: 22 Dec 2006  
BioTechnology Law Group  
527 N. Highway 101, Suite E  
Solana Beach, CA 92075-1173  
Telephone: (858) 350-9690  
Fax: (858) 350-9691  
Email: dan@biotechnologylawgroup.com

By



Daniel M. Chambers  
Reg. No. 34,561

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	1 6,757
Filing Date	December 4, 2004
First Named Inventor	Rabussay, Dietmar P.
Group Art Unit	To Be Assigned - 1655
Examiner Name	To Be Assigned Tate

Sheet 1 of 1

Attorney Docket No: GTI-1490-US

**US PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1.	US 6,120,493	19 Sep 2000	Hoffman	
	A2.	US 5,810,762	22 Sep 1998	Hofmann	
	A3.	US 5,439,440	08 Aug 1995	Hofmann	
	A4.	US 5,273,525	28 Dec 1993	Hofmann	
	A5.	US 5,128,257	07 Jul 1992	Baer	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
	A6.	WO 01/07585 A	01 Feb 2001	Regents Univ. of CA		
	A7.	WO 99/22810	14 May 1999	Hisamitsu Pharm. Co.		

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A8.	BOON, T., "Teaching the immune system to fight cancer," <i>Scientific American</i> 268(3):82-89 (March 1993)	
	A9.	DEV et al., "Medical applications of electroporation," <i>IEEE Transactions on plasma science</i> , 28(1):206-223 (2000)	
	A10.	FEWELL et al., "Gene therapy for the treatment of hemophilia B using PINC-formulated plasmid delivered to muscle with electroporation," <i>Molecular Therapy</i> 3:574-583 (2000)	
	A11.	GLASSPOOL-MALONE et al., "Efficient nonviral cutaneous transfection," <i>Molecular Therapy</i> 2:140-146 (2000)	
	A12.	HOFMANN et al., "Electroporation therapy of solid tumors," <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> 16(6):523-569 (1999)	
	A13.	TOMOV et al., "Are the stainless steel electrodes inert?," <i>Bioelectrochemistry</i> 51(2):207-209 (2000)	
	A14.	ZELPHATI et al., "PNA-dependent gene chemistry: stable coupling of peptides and oligonucleotides to plasmid DNA," <i>Biotechniques</i> 28:304-310; 312-314; 316 (2000)	
	A15.	ZHANG et al., "Enhanced delivery of naked DNA to the skin by non-invasive in vivo electroporation," <i>Biochim. Biophys. Acta</i> 1572(1):1-9 (2002)	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.R.T./

EXAMINER


/Christopher Tate/

DATE CONSIDERED

12/14/2009

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached



# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

192

Application Number

10/516,757

Filing Date

December 4, 2004

First Named Inventor

RABUSSAY, Dietmar P.

Art Unit

To Be Assigned

Examiner Name

To Be Assigned

Attorney Docket Number

GTI-1490-US

## ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	* Transmittal (1 page)
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	* IDS (1) (2 pages)
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	* SB/08 Form (1 page)
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	<input type="checkbox"/> Landscape Table on CD	* 10 References (10 items)
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	* Return Postcard (1 item)

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	BioTechnology Law Group		
Signature			
Printed name	Daniel M. Chambers		
Date	22 Dec 2006	Reg. No.	34,561

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Daniel M. Chambers	Date	22 Dec 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.